Fig. 10: KJ103 reduced pre-existing AAV2 NAb activity. | Gene Therapy

Fig. 10: KJ103 reduced pre-existing AAV2 NAb activity.

From: Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials

Fig. 10

The titers of AAV2 Nab before and after administration were individually shown, grouped by their pre-dose titer as <1:1000 (A), 1:1000 ~ 1:2000 (B) and >1:2000 (C). The naming convention “R+number” represents the codes for different volunteers, with the corresponding dose indicated by the suffix. D The temporal variation of NAb, F(ab’)2 and IgG levels in the selected volunteers. Details regarding the selection and grouping referred to in the main text.

Back to article page